This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010;28(2):109-11.

doi: 10.2165/11530860-000000000-00000.

Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit

Devidas Menon¹, Christopher J McCabe, Tania Stafinski, Richard Edlin; signatories to the Consensus Statement

Collaborators, Affiliations

Collaborators

signatories to the Consensus Statement:
Joan Berezanski, Andrew Briggs, Kalipso Chalkidou, Cindy Cooper, Richard Edlin, Mohamed El-Shayeb, Brendan Kearney, Deborah Marshall, Christopher McCabe, Devidas Menon, Tania Stafinski, Sean Tunis, Danielle Whicher

Affiliation

¹ Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada.

PMID: 20085388
DOI: 10.2165/11530860-000000000-00000

Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit

Devidas Menon et al. Pharmacoeconomics. 2010.

. 2010;28(2):109-11.

doi: 10.2165/11530860-000000000-00000.

Authors

Devidas Menon¹, Christopher J McCabe, Tania Stafinski, Richard Edlin; signatories to the Consensus Statement

Collaborators

signatories to the Consensus Statement:
Joan Berezanski, Andrew Briggs, Kalipso Chalkidou, Cindy Cooper, Richard Edlin, Mohamed El-Shayeb, Brendan Kearney, Deborah Marshall, Christopher McCabe, Devidas Menon, Tania Stafinski, Sean Tunis, Danielle Whicher

Affiliation

¹ Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada.

PMID: 20085388
DOI: 10.2165/11530860-000000000-00000

No abstract available

PubMed Disclaimer

Similar articles

Access with evidence development schemes: a framework for description and evaluation.
McCabe CJ, Stafinski T, Edlin R, Menon D; Banff AED Summit. McCabe CJ, et al. Pharmacoeconomics. 2010;28(2):143-52. doi: 10.2165/11530850-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085390
Access with evidence development in the UK: past experience, current initiatives and future potential.
Briggs A, Ritchie K, Fenwick E, Chalkidou K, Littlejohns P. Briggs A, et al. Pharmacoeconomics. 2010;28(2):163-70. doi: 10.2165/11531410-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085392
National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES, Kim JA, Lee EK. Kim ES, et al. Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):401-409. doi: 10.1080/14737167.2017.1276828. Epub 2017 Jan 3. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28010146
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
Stafinski T, McCabe CJ, Menon D. Stafinski T, et al. Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085389 Review.
Concepts of quality and the provision of periodontal care: a survey.
Marcus M, Spolsky V. Marcus M, et al. J Periodontol. 1998 Feb;69(2):228-40. doi: 10.1902/jop.1998.69.2.228. J Periodontol. 1998. PMID: 9526923 Review.

See all similar articles

Cited by

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.
Sculpher M. Sculpher M. Pharmacoeconomics. 2010;28(5):347-9. doi: 10.2165/11535680-000000000-00000. Pharmacoeconomics. 2010. PMID: 20402539 No abstract available.
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T, Menon D, Davis C, McCabe C. Stafinski T, et al. Clinicoecon Outcomes Res. 2011;3:117-86. doi: 10.2147/CEOR.S14407. Epub 2011 Aug 30. Clinicoecon Outcomes Res. 2011. PMID: 22046102 Free PMC article.
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Michelsen S, et al. Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020. Front Pharmacol. 2020. PMID: 33363468 Free PMC article. Review.
Access with evidence development: the US experience.
Mohr PE, Tunis SR. Mohr PE, et al. Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085391
We know accurately only when we know little.
MacLeod S, Mitton C. MacLeod S, et al. Pharmacoeconomics. 2010;28(2):105-7. doi: 10.2165/11531510-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085387 No abstract available.

See all "Cited by" articles

References

1. Pharmacoeconomics. 2010;28(2):143-52 - PubMed
1. Pharmacoeconomics. 2010;28(2):153-62 - PubMed
1. BMJ. 2003 Feb 15;326(7385):388-92 - PubMed
1. Pharmacoeconomics. 2010;28(2):163-70 - PubMed
1. Pharmacoeconomics. 2010;28(2):113-42 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer